{"id":"W4406869312","doi":"10.1200/jco.2025.43.4_suppl.448","title":"Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Pembrolizumab; Medicine; Trastuzumab; Metastatic melanoma; Cancer research; Gemcitabine; Nivolumab; Internal medicine; Oncology; Cancer; Immunotherapy; Melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004152421,0.0008474716,0.001327337,0.0007062565,0.0002841409,0.001195927,0.001157394,0.001077011,0.004112319],"category_scores_gemma":[0.00302622,0.0003420069,0.002035899,0.0009007938,0.0002495114,0.0006302131,0.0004947841,0.001698947,0.001112777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001582037,"about_ca_system_score_gemma":0.001760155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003407475,"about_ca_topic_score_gemma":0.006334883,"domain_scores_codex":[0.9980776,0.0007734929,0.0001822648,0.0001905141,0.0005291792,0.000246808],"domain_scores_gemma":[0.9964783,0.0008476245,0.000989154,0.0003106628,0.0007362965,0.000638062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2264653,0.01493706,0.04772131,0.003250151,0.006473512,0.0009246095,0.0004212258,0.006196793,0.08603963,0.0005431992,0.1279156,0.4791117],"study_design_scores_gemma":[0.06682595,0.2287668,0.3099511,0.0008597096,0.016736,0.005541344,0.0002972998,0.002883727,0.05878096,0.0007548534,0.3083809,0.0002212242],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7943311,0.04886445,0.004031151,0.005052413,0.001166788,0.00401354,0.1119184,0.0007206536,0.02990154],"genre_scores_gemma":[0.8053088,0.01911193,0.01023948,0.01128699,0.0006755652,0.002614914,0.1407107,0.0003213667,0.009730288],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004152421,"threshold_uncertainty_score":0.02196032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0508744364437234,"score_gpt":0.3738558524944282,"score_spread":0.3229814160507048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}